cagrilintide semaglutide phase 2 weight loss In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body than placebo at 68 weeks. Full trial results VisualAbstract: Cagrilintide-Semaglutide is Effective for
VisualAbstract: Cagrilintide Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes 2 Minute Medicine New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https: nej.md 444aW7f CagrilintideSemaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https: nej.md 4ehQwLk CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension CagriSema: a novel dual pathway approach to target obesity and its complications Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet
Pay in 4 interest-free payments of $6.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11




00845-X/asset/6bf09e64-6415-496f-bd9e-0ea3f08fb1c8/main.assets/gr3.jpg)